Pharmacokinetic comparison of Pyritinol in rats under normoxic and hypoxic condition

doi:10.3969/j.issn.1006-7795.2017.02.016

Abstract

Abstract: Objective To determine and compare the pharmacokinetic parameters of Pyritinol in rat plasma under normoxic and hypoxic conditions. Methods An effective and rapid ultra-performance liquid chromatography with tandem mass spectrometry (UPLC-MS/MS) method with positive electrospray ionization source was successfully developed and validated for quantification of Pyritinol in rat plasma. Sprague-Dawley rats were randomly divided into the hypoxia and normoxic groups. Each rat obtained a single dose of Pyritinol through intragastric administration. The plasma samples were drawn through jugular veins to measure the drug concentrations at different times. The pharmacokinetics parameters were processed via the DAS 2.0 software, and the comparison of main pharmacokinetic parameters in rats between normoxic and hypoxic groups was calculated by the SPSS software via an independent sample t test method. Results The main pharmacokinetic parameters of Pyritinol between the hypoxia and the normoxic rats were as follows:the AUC_(0-t) (88.26±9.86) ng·h·mL^-1 and (80.67±8.95)ng·h·mL^-1, MRT_(0-t) (4.14±0.32)h and (3.67±0.26)h, t_1/2 (3.72±1.82) h and (3.14±1.42)h, t_max (0.58±0.20)h and (0.67±0.26)h, C_max(30.12±2.36)ng/mL and (20.05±1.31)ng/mL, respectively. The values of C_max and MRT(o-t) for Pyritinol in hypoxic rats were statistically lower than that in normoxic rats, and other main pharmacokinetic parameters did not have significant differences. Conclusion Hypoxia affects drug peak concentration in rats, and furthermore affects the steady-state blood concentrations of drugs, which could interfere the therapeutic effect and toxic reaction.

Key words: Pyritinol, pharmacokinetics, hypoxia, normoxia, UPLC-MS/MS

CLC Number:

Yang Yifan, Qin Yi, Xu Weizhe, Xu Pingxiang, Xue Ming. Pharmacokinetic comparison of Pyritinol in rats under normoxic and hypoxic condition[J]. Journal of Capital Medical University, 2017, 38(2): 232-237.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2017.02.016

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2017/V38/I2/232

References

[1] Ran R, Xu H, Lu A, et al. Hypoxia preconditioning in thebrain[J]. Dev Neurosci,2005, 27(2-4): 87-92.
[2] 张娟玲, 李向阳. 高原低氧影响药物代谢的研究进展[J]. 药学学报,2015,50(9):1073-1079.
[3] 郑悦,嵇扬. 抗缺氧研究常用动物模型及抗缺氧药物[J]. 解放军药学学报,2010,26(2):170-173.
[4] Zafren K. Prevention of high altitude illness[J]. Travel Med Infec Dis, 2014, 12(1):29-39.
[5] Johnson N J, Luks A M. High-Altitude Medicine[J]. Med Clin North Am,2016,100(2):357-369.
[6] 张健. 盐酸吡硫醇的药理作用与临床应用[J]. 中国热带医学,2005,5(2):394-395.
[7] Jiménez-Andrade G Y,Reyes-García R G,Sereno G,et al. Pyritinol reduces nociception and oxidative stress in diabetic rats[J]. Eur J Pharmacol,2008,590(1-3):170-176.
[8] Alkuraishy H M, Al-Gareeb Al,Albuhadilly A K. Vinpocetine and Pyritinol:a new model for blood rheological modulation in cerebrovascular disorders-a randomized controlled clinical study[J]. Bio Med Res Int,2014,2014: 324307.
[9] 过治军,石灵,冯素玲,等. 邻菲啰啉-Fe(Ⅱ)光度法间接测定盐酸吡硫醇[J]. 分析试验室,2011,30(12):5-7.
[10] Aranda M, Morlock G E. Quantification of Pyritinol in solid pharmaceutical formulation by high-performance thin-layer chromatography-ultraviolet detection and selectivity evaluation by mass spectrometry[J]. J Chromatogr B, 2010,33(7-8):957-971.
[11] 孟繁娜,唐星. pH值对盐酸吡硫醇水溶液稳定性的影响[J]. 中国医院药学杂志,2007,27(3):400-403.
[12] 何静思,薛大权. 盐酸吡硫醇与硫酸镁在几种输液中的稳定性研究[J]. 数理医药学杂志,2010,23(3):355-357.
[13] 秦春雨,周滔,宫雯雯,等. UPLC-MS/MS法测定大鼠血浆中雷公藤内酯醇及其药代动力学[J]. 首都医科大学学报,2015,36(1):121-126.
[14] 李鹏飞,王淑民,张茜,等. LC-MS/MS法测定人血浆中氨基葡萄糖的浓度[J]. 首都医科大学学报,2013,34(5):715-719.
[15] 李金卓,潘磊,冯佳,等. 盐酸吡硫醇脂质体在大鼠体内药动学研究[J]. 现代药物与临床,2013,28(5):700-703.
[16] 徐唯哲,赵妍,秦一,等.低氧与常氧状态下芍药苷在大鼠体内的药代动力学比较[J].国际药学杂志,2016,43(2):336-340.